Nitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice

Giuseppe D'Antona, Anna Mascaro, Angela Monopoli, Daniela Miglietta, Ennio Ongini, Roberto Bottinelli

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: Myopathy is the most common side effect of statins. Because nitric oxide (NO) has a key role in regulating skeletal muscle function, we studied whether the NO-donating atorvastatin NCX 6560 could show a better profile on skeletal muscle function and structure compared with atorvastatin. Methods: C57BL/6 mice received atorvastatin 40 mg/kg/day or an equivalent dose of NCX 6560 for 2 months. Muscle function assessed by treadmill test, serum creatine kinase (CK) activity, citrate synthase (CS) activity, and muscle histology were evaluated. Results: Atorvastatin significantly (P <0.001) reduced muscle endurance, increased serum CK by 6-fold, and induced muscle fiber atrophy. Conversely, NCX 6560 preserved muscle function, prevented CK increase and did not modify muscle structure. Interestingly, atorvastatin reduced CS activity, a marker for mitochondrial function, in gastrocnemius, diaphragm, and heart, whereas NCX 6560 prevented such decrease. Conclusions: These findings suggest that NO may prevent statin-induced myopathy.

Original languageEnglish
Pages (from-to)72-80
Number of pages9
JournalMuscle and Nerve
Volume47
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Nitric Oxide
Skeletal Muscle
Muscles
Creatine Kinase
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Citrate (si)-Synthase
Muscular Diseases
Muscular Atrophy
Diaphragm
Serum
Exercise Test
Inbred C57BL Mouse
Histology
Atorvastatin Calcium
NCX 6560

Keywords

  • Atorvastatin
  • NCX 6560
  • Nitric oxide
  • Skeletal muscle
  • Statin myopathy

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)
  • Physiology

Cite this

Nitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice. / D'Antona, Giuseppe; Mascaro, Anna; Monopoli, Angela; Miglietta, Daniela; Ongini, Ennio; Bottinelli, Roberto.

In: Muscle and Nerve, Vol. 47, No. 1, 01.2013, p. 72-80.

Research output: Contribution to journalArticle

D'Antona, Giuseppe ; Mascaro, Anna ; Monopoli, Angela ; Miglietta, Daniela ; Ongini, Ennio ; Bottinelli, Roberto. / Nitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice. In: Muscle and Nerve. 2013 ; Vol. 47, No. 1. pp. 72-80.
@article{4b8e872542fd4888849a2184f0a0c9e1,
title = "Nitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice",
abstract = "Introduction: Myopathy is the most common side effect of statins. Because nitric oxide (NO) has a key role in regulating skeletal muscle function, we studied whether the NO-donating atorvastatin NCX 6560 could show a better profile on skeletal muscle function and structure compared with atorvastatin. Methods: C57BL/6 mice received atorvastatin 40 mg/kg/day or an equivalent dose of NCX 6560 for 2 months. Muscle function assessed by treadmill test, serum creatine kinase (CK) activity, citrate synthase (CS) activity, and muscle histology were evaluated. Results: Atorvastatin significantly (P <0.001) reduced muscle endurance, increased serum CK by 6-fold, and induced muscle fiber atrophy. Conversely, NCX 6560 preserved muscle function, prevented CK increase and did not modify muscle structure. Interestingly, atorvastatin reduced CS activity, a marker for mitochondrial function, in gastrocnemius, diaphragm, and heart, whereas NCX 6560 prevented such decrease. Conclusions: These findings suggest that NO may prevent statin-induced myopathy.",
keywords = "Atorvastatin, NCX 6560, Nitric oxide, Skeletal muscle, Statin myopathy",
author = "Giuseppe D'Antona and Anna Mascaro and Angela Monopoli and Daniela Miglietta and Ennio Ongini and Roberto Bottinelli",
year = "2013",
month = "1",
doi = "10.1002/mus.23465",
language = "English",
volume = "47",
pages = "72--80",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Nitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice

AU - D'Antona, Giuseppe

AU - Mascaro, Anna

AU - Monopoli, Angela

AU - Miglietta, Daniela

AU - Ongini, Ennio

AU - Bottinelli, Roberto

PY - 2013/1

Y1 - 2013/1

N2 - Introduction: Myopathy is the most common side effect of statins. Because nitric oxide (NO) has a key role in regulating skeletal muscle function, we studied whether the NO-donating atorvastatin NCX 6560 could show a better profile on skeletal muscle function and structure compared with atorvastatin. Methods: C57BL/6 mice received atorvastatin 40 mg/kg/day or an equivalent dose of NCX 6560 for 2 months. Muscle function assessed by treadmill test, serum creatine kinase (CK) activity, citrate synthase (CS) activity, and muscle histology were evaluated. Results: Atorvastatin significantly (P <0.001) reduced muscle endurance, increased serum CK by 6-fold, and induced muscle fiber atrophy. Conversely, NCX 6560 preserved muscle function, prevented CK increase and did not modify muscle structure. Interestingly, atorvastatin reduced CS activity, a marker for mitochondrial function, in gastrocnemius, diaphragm, and heart, whereas NCX 6560 prevented such decrease. Conclusions: These findings suggest that NO may prevent statin-induced myopathy.

AB - Introduction: Myopathy is the most common side effect of statins. Because nitric oxide (NO) has a key role in regulating skeletal muscle function, we studied whether the NO-donating atorvastatin NCX 6560 could show a better profile on skeletal muscle function and structure compared with atorvastatin. Methods: C57BL/6 mice received atorvastatin 40 mg/kg/day or an equivalent dose of NCX 6560 for 2 months. Muscle function assessed by treadmill test, serum creatine kinase (CK) activity, citrate synthase (CS) activity, and muscle histology were evaluated. Results: Atorvastatin significantly (P <0.001) reduced muscle endurance, increased serum CK by 6-fold, and induced muscle fiber atrophy. Conversely, NCX 6560 preserved muscle function, prevented CK increase and did not modify muscle structure. Interestingly, atorvastatin reduced CS activity, a marker for mitochondrial function, in gastrocnemius, diaphragm, and heart, whereas NCX 6560 prevented such decrease. Conclusions: These findings suggest that NO may prevent statin-induced myopathy.

KW - Atorvastatin

KW - NCX 6560

KW - Nitric oxide

KW - Skeletal muscle

KW - Statin myopathy

UR - http://www.scopus.com/inward/record.url?scp=84871268381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871268381&partnerID=8YFLogxK

U2 - 10.1002/mus.23465

DO - 10.1002/mus.23465

M3 - Article

VL - 47

SP - 72

EP - 80

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 1

ER -